

**FOR IMMEDIATE RELEASE**

March 26, 2007

Asahi Kasei Pharma Corporation

Eisai Co., Ltd.

**Asahi Kasei Pharma Corporation and Eisai Co., Ltd.  
Signed License Agreement for Vasodilator *Eiril*<sup>®</sup> in Korea**

Asahi Kasei Pharma Corporation (AKP, Headquarters: Chiyoda-ku, Tokyo, President: Kei Oe) and Eisai Korea Inc. (Headquarters: Seoul, Korea, President: Cho Byoung Chic), a subsidiary of Eisai Co., Ltd. (Headquarters: Bunkyo-ku, Tokyo, President and CEO: Haruo Naito), signed a license agreement for Vasodilator *Eiril*<sup>®</sup> (Injectable formulation, generic name: fasudil hydrochloride). By this agreement, which was signed on March 23, 2007 by both companies, AKP will grant Eisai Korea Inc. the right for development and marketing of *Eiril*<sup>®</sup> in Korea. Eisai Korea Inc. will start development of *Eiril*<sup>®</sup> in Korea in order to submit an application for new drug approval in the region.

*Eiril*<sup>®</sup> is indicated for prevention of cerebral vasospasm and ensuing cerebral ischemia following surgery for subarachnoid hemorrhage. Employing a new mechanism called a “*Rho-Kinase*” inhibiting activity, the drug prevents contraction of vascular smooth muscle and improves functional disorders associated with cerebral vasospasm or cerebral ischemia.

Eisai Korea Inc. is actively expanding business development in the region including the globally marketed Alzheimer's disease treatment *Aricept*<sup>®</sup>. The addition of *Eiril*<sup>®</sup> to the product lineup will bring greater synergy and enable further contributions for the benefits to patients. Meanwhile, AKP can utilize Eisai Korea Inc.'s expertise in neurology field to achieve a rapid launch of the drug and widespread use by the patients in the region.

Introduction of *Eiril*<sup>®</sup> to Korea, which will be made possible by this agreement following the market introduction of the product in China, will further enhance the corporate presence in their respective fields of focus and increase the recognition for *Eiril*<sup>®</sup> in Korea for the greater benefits to the patients in the region.

**Contacts:**

<p>Asahi Kasei Pharma Corporation General Affairs Department TEL: +81-3-3259-5777</p> <p>Asahi Kasei Corporation Corporate Communications TEL: +81-3-3507-2060</p>	<p>Eisai Co., Ltd. Corporate Communications Department TEL: +81-3-3817-5120</p>
--	---